

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

Protocol	Description	Size	Trial Collaborators	Start Date*	Sites	Stage
<b>HVTN 096/EV04</b>	A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus NYVAC + AIDSVAX B/E, and DNA alone versus DNA + AIDSVAX B/E when followed by NYVAC + AIDSVAX B/E boosts in healthy, HIV-1 uninfected adult participants	96	HVTN BMGF IPPOX EuroVacc GSID USMHRP DAIDS	Aug 2012	Lausanne	Annual health/AESI contact(s)
<b>HVTN 106</b>	A phase 1 randomized, double-blind, placebo controlled clinical trial to evaluate the safety and immunogenicity of an HIV-1 vaccine regimen of DNA prime with 3 different HIV-1 envelope inserts (Nat-B env, CON-S env, and Mosaic env) with MVA-CMDR boost in healthy, HIV-1-uninfected adults	105	HVTN CHAVI-ID DAIDS EuroVacc LANL USMHRP	Jan 2015	Atlanta - Hope Clinic; Birmingham; Boston - Brigham; Boston - Fenway; Lausanne; San Francisco; Seattle	Annual health/AESI contact(s)
<b>HVTN 107</b>	A Phase 1/2a partially double-blinded, randomized clinical trial to characterize the safety and immunogenicity of clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 alone, with MF59® adjuvant, and with alum adjuvant in healthy, HIV-uninfected adult participants	132	HVTN DAIDS GSK Sanofi	Jun 2017	Cape Town - Emavundleni; Durban - eThekweni; Harare - Seke South; Maputo; Soweto - Bara; Tembisa - Clinic 3	Follow-up (closed to accrual)
<b>HVTN 108</b>	A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants	334	HVTN DAIDS BMGF GSK IPPOX	Dec 2016	Birmingham; Boston - Brigham; Boston - Fenway; Cape Town - Emavundleni; Durban - Verulam; Durban - eThekweni; Klerksdorp; Ladysmith; Nashville; New York - NYBC; New York - Physicians & Surgeons; Rochester; Seattle; Soshanguve; Soweto - Bara; Soweto - Kiptown; Tembisa - Clinic 3	Follow-up (closed to accrual)
<b>HVTN 110</b>	A Phase 1 clinical trial to evaluate the safety and immunogenicity of orally-administered replication-competent Adenovirus type-4 HIV vaccine regimens in healthy, HIV-uninfected adult participants	60	HVTN PaxVax GSID USMHRP DAIDS	Mar 2015	Atlanta - Hope Clinic; Birmingham; Boston - Brigham; Boston - Fenway; Cleveland; Nashville; New York - NYBC; New York - Physicians & Surgeons; Philadelphia; Rochester; San Francisco; Seattle	Annual health/AESI contact(s)

\*First participant enrolled

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

Protocol	Description	Size	Trial Collaborators	Start Date*	Sites	Stage
<b>HVTN 112</b>	A phase 1 trial to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 nef/tat/vif, env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy HIV-uninfected adult participants	15	HVTN DAIDS Profectus Ichor	Apr 2016	Cleveland; Philadelphia	Follow-up (closed to accrual)
<b>HVTN 114</b>	A phase I clinical trial to evaluate the immunogenicity of AIDSVAX® B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205	100	HVTN DAIDS GeoVax GSID	Feb 2017	Atlanta - Hope Clinic; Birmingham; Boston - Brigham; Iquitos; Lima - Barranco; Nashville; New York - NYBC; New York - Physicians & Surgeons; Rochester; San Francisco; Seattle	Annual health/AESI contact(s)
<b>HVTN 115</b>	A Phase I clinical trial to evaluate the safety and immunogenicity of CH505 Envs adjuvanted with GLA-SE, administered alone or with DNA mosaic Env, in healthy, HIV-uninfected adult participants	132	HVTN DAIDS CHAVI IDRI	Oct 2017	Birmingham; New York - NYBC; New York - Physicians & Surgeons; Rochester	Enrolling
<b>HVTN 116</b>	A phase 1 clinical trial to evaluate the safety, pharmacokinetics, and anti-viral activity of VRC HIVMAB060 00 AB (VRC01) and VRC HIVMAB080 00 AB (VRC01LS) in the serum and mucosa of healthy, HIV-uninfected adult participants	74	HVTN VRC DAIDS	Mar 2017	Cape Town - Groote Schuur; Cleveland; Philadelphia; Seattle	Follow-up (closed to accrual)
<b>HVTN 119</b>	A phase 1 clinical trial to evaluate the safety and immunogenicity of pDNA vaccines expressing HIV M Group p24Gag conserved elements and/or p55Gag, administered with IL-12 pDNA by intramuscular electroporation, in healthy, HIV-uninfected adult participants	56	HVTN DAIDS Profectus University of Washington Ichor NCI	Nov 2017	Atlanta - Hope Clinic; Cleveland; San Francisco	Follow-up (closed to accrual)

\*First participant enrolled

Printed 1/9/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

Protocol	Description	Size	Trial Collaborators	Start Date*	Sites	Stage
<b>HVTN 120</b>	A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants	320	HVTN DAIDS BMGF Sanofi GSK	Feb 2018	Atlanta - Hope Clinic; Boston - Brigham; Boston - Fenway; Cleveland; Durham; Harare - Seke South; Lusaka - Matero; Mbeya; Nashville; New York - Physicians & Surgeons; Philadelphia; Rochester; San Francisco; Seattle	Follow-up (closed to accrual)
<b>HVTN 122</b>	A Phase 1 double-blind, randomized clinical trial to evaluate the safety and immunogenicity of MHRP recombinant trimeric gp145 Env in healthy, HIV-1 uninfected adult participants	45	HVTN USMHRP DAIDS	Jan 2018	New York - NYBC; New York - Physicians & Surgeons; Philadelphia	Follow-up (closed to accrual)
<b>HVTN 124</b>	A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, E)/gag (C) DNA and gp 120 (A,B,C,E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as either a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1 uninfected adult participants	60	HVTN DAIDS U Mass	Apr 2018	Atlanta - Hope Clinic; Birmingham; Boston - Fenway; Cleveland; Nashville; Philadelphia; Rochester	Enrolling
<b>HVTN 127/HPTN 087</b>	A phase 1 clinical trial to evaluate the safety and drug levels of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses intravenously, subcutaneously, and intramuscularly in different dosing schedules to healthy, HIV-uninfected adults	100	HVTN HPTN DAIDS VRC	Feb 2018	Atlanta - Ponce de Leon; Birmingham; Boston - Brigham; Boston - Fenway; Chapel Hill; Lausanne; New York - Physicians & Surgeons	Follow-up (closed to accrual)
<b>HVTN 702</b>	A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa	5400	HVTN GSK DAIDS Sanofi Pasteur BMGF MRC	Oct 2016	Cape Town - Emavundleni; Cape Town - Khayelitsha; Durban - Isipingo; Durban - Verulam; Durban - eThekweni; Klerksdorp; Ladysmith; Medunsa; Mthatha; Rustenburg; Soshanguve; Soweto - Bara; Soweto - Kiptown; Tembisa - Clinic 3	Enrolling

\*First participant enrolled

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

Protocol	Description	Size	Trial Collaborators	Start Date*	Sites	Stage
<b>HVTN 703/HPTN 081</b>	A phase 2b study to evaluate the efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection	1900	HVTN HPTN DAIDS VRC	May 2016	Blantyre; Cape Town - Grooten Schuur; Durban - Botha's Hill; Durban - Chatsworth; Durban - eThekwini; Gaborone; Harare - Parirenyatwa; Harare - Seke South; Harare - Spilhaus; Hillbrow; Johannesburg - Ward 21; Kisumu; Klerksdorp; Lilongwe; Mamelodi; Maputo; Mbeya; Rustenburg; Soweto - Bara; Tembisa - Clinic 3; Vulindlela	Follow-up (closed to accrual)
<b>HVTN 704/HPTN 085</b>	A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men	2700	HVTN HPTN DAIDS VRC	Apr 2016	Atlanta - Hope Clinic; Atlanta - Ponce de Leon; Birmingham; Boston - Brigham; Boston - Fenway; Chapel Hill; Cleveland; Iquitos; Lausanne; Lima - Barranco; Lima - San Marcos; Lima - San Miguel; Lima - Via Libre; Los Angeles - Vine Street; Nashville; New York - Bronx Prevention; New York - Harlem Prevention; New York - NYBC; New York - Physicians & Surgeons; Newark; Philadelphia; Rio de Janeiro; Rochester; San Francisco; Seattle; Washington - DC	Follow-up (closed to accrual)

\*First participant enrolled

Printed 1/9/2019

Ongoing HVTN Trials: Enrolling, In Follow-up, Annual Health/AESI Contact(s)

Protocol	Description	Size	Trial Collaborators	Start Date*	Sites	Stage
<b>HVTN 705/HPX 2008</b>	A multicenter, randomized, double-blind, placebo-controlled phase 2b efficacy study of a heterologous prime/boost vaccine regimen of Ad26.Mos4.HIV and aluminum phosphate- adjuvanted Clade C gp140 in preventing HIV-1 infection in women in sub-Saharan Africa	2600	HVTN Janssen DAIDS BMGF	Nov 2017	Bloemfontein; Cape Town - Emavundleni; Cape Town - Khayelitsha; Durban - Chatsworth; Durban - Isipingo; Durban - Tongaat; Durban - Verulam; Durban - eThekwini; Elandsdoorn; Harare - Seke South; Harare - St. Mary's; Klerksdorp; Ladysmith; Lilongwe; Lusaka - Matero; Lusaka - ZEHRP; Mamelodi; Maputo; Masiphumelele; Medunsa; Mthatha; Ndola; Rustenburg; Soshanguve; Soweto - Bara; Soweto - Kliptown; Tembisa - Clinic 4	Enrolling

\*First participant enrolled